Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 10/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 4/20 | 0.66 |
| ▸ | MLST8 | Q9BVC4 | 4/20 | 0.66 |
| ▸ | PIM1 | P11309 | 6/20 | 0.54 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23036903 | 0.88 | MTOR (0.79) | MTORRPTORMLST8PIM1CISD1 | |
| SCHEMBL23036910 | 0.80 | MTOR (0.67) | MTORRPTORMLST8PIM1MEN1 | |
| SCHEMBL23036936 | 0.80 | MTOR (1.00) | MTORRPTORMLST8PIM1CISD1 | |
| SCHEMBL23036920 | 0.78 | MTOR (1.00) | MTORRPTORMLST8PIM1CISD1 | |
| SCHEMBL29249412 | 0.76 | MTOR (0.62) | MTORRPTORMLST8MEN1ALDH1A1 | |
| SCHEMBL8307310 | 0.75 | GSK3B (0.74) | MTORRPTORMLST8PIM1CISD1 | |
| SCHEMBL8307311 | 0.75 | GSK3B (0.74) | MTORRPTORMLST8PIM1CISD1 | |
| SCHEMBL23036944 | 0.74 | MTOR (0.79) | MTORRPTORMLST8PIM1HPGD | |
| SCHEMBL23036915 | 0.73 | MTOR (1.00) | MTORRPTORMLST8PIM1CISD1 | |
| SCHEMBL14305788 | 0.73 | KMT2A (0.76) | MTORRPTORMLST8MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2023-05-16 | — | — | US | claimed |
| US-20210292314-A1 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2021-09-23 | — | — | US | claimed |
| EP-3786163-A1 | NOVEL COMPOUND AS MTOR INHIBITOR AND USE THEREOF | Medicinal Bioconvergence Research Center (KR) | 2021-03-03 | — | — | EP | claimed |
| CN-112368279-A | Novel compounds as mTOR inhibitors and uses thereof | 医药生命融合研究团 | 2021-02-12 | — | — | CN | claimed |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2023-05-16 | — | — | US | disclosed |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2023-05-16 | — | — | US | disclosed |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2023-05-16 | — | — | US | disclosed |
| US-20210292314-A1 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2021-09-23 | — | — | US | disclosed |
| US-20210292314-A1 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2021-09-23 | — | — | US | disclosed |
| EP-3786163-A1 | NOVEL COMPOUND AS MTOR INHIBITOR AND USE THEREOF | Medicinal Bioconvergence Research Center (KR) | 2021-03-03 | — | — | EP | disclosed |
| CN-112368279-A | Novel compounds as mTOR inhibitors and uses thereof | 医药生命融合研究团 | 2021-02-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 8/4885 |
| US-20210292314-A1 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.